NCT03691493: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

NCT03691493
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Bone
Additional Notes: One previous line of chemotherapy in advanced disease is allowed
Exclusions: Patients with untreated brain metastases or unstable/progressive brain metastases
https://ClinicalTrials.gov/show/NCT03691493

Comments are closed.

Up ↑